Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro

Satoru Yamada, Natsuko Ano, Kyoko Toda, Akira Kitaoka, Kaoru Shiono, Gaku Inoue, Koichiro Atsuda, Junichiro Irie

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

To examine the effects of telmisartan on peroxisome proliferator-activated receptor γ activation, we compared the effects of telmisartan with those of candesertan on adipocytokines and glucose and lipid metabolism in vivo and in vitro. In vivo, 56 patients with both type 2 diabetes and hypertension were enrolled and randomized to receive either telmisartan (40 mg) or candesartan (8 mg) for 3 months. Serum adiponectin, HbA1c levels, lipid profiles and blood pressure were recorded at the beginning and 3 months later. In vitro, differentiated 3T3-L1 adipocytes: were treated with telmisartan, candesartan, ploglitazone or vehicle for 24 h, and then adiponectin mRNA and protein levels were measured. The results showed that most of the metabolic parameters, including the lipid profiles, did not change significantly during the study in either group. However, the changes in serum adiponectin and plasma glucose over 3 months were significantly greater in the telmisartan group than in the candesartan group. In vitro, although the protein level of adiponectin was not significantly elevated, the mRNA expression of adiponectin was elevated 1.5-fold by telmisartan in 3T3-L1 adipocytes. Our findings suggest that telmisartan may have beneficial effects in type 2 diabetes beyond its antihypertensive effect.

Original languageEnglish
Pages (from-to)601-606
Number of pages6
JournalHypertension Research
Volume31
Issue number4
DOIs
Publication statusPublished - 2008 Apr
Externally publishedYes

Fingerprint

Adiponectin
Adipocytes
Type 2 Diabetes Mellitus
Lipids
Glucose
Messenger RNA
Peroxisome Proliferator-Activated Receptors
Adipokines
In Vitro Techniques
candesartan
telmisartan
Serum
Lipid Metabolism
Antihypertensive Agents
Proteins
Blood Pressure
Hypertension

Keywords

  • Adiponectin
  • Candesartan
  • Peroxisome proliferator-activated receptor γ
  • Telmisartan

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro. / Yamada, Satoru; Ano, Natsuko; Toda, Kyoko; Kitaoka, Akira; Shiono, Kaoru; Inoue, Gaku; Atsuda, Koichiro; Irie, Junichiro.

In: Hypertension Research, Vol. 31, No. 4, 04.2008, p. 601-606.

Research output: Contribution to journalArticle

Yamada, S, Ano, N, Toda, K, Kitaoka, A, Shiono, K, Inoue, G, Atsuda, K & Irie, J 2008, 'Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro', Hypertension Research, vol. 31, no. 4, pp. 601-606. https://doi.org/10.1291/hypres.31.601
Yamada, Satoru ; Ano, Natsuko ; Toda, Kyoko ; Kitaoka, Akira ; Shiono, Kaoru ; Inoue, Gaku ; Atsuda, Koichiro ; Irie, Junichiro. / Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro. In: Hypertension Research. 2008 ; Vol. 31, No. 4. pp. 601-606.
@article{91a7766647664a21860015a44606bed8,
title = "Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro",
abstract = "To examine the effects of telmisartan on peroxisome proliferator-activated receptor γ activation, we compared the effects of telmisartan with those of candesertan on adipocytokines and glucose and lipid metabolism in vivo and in vitro. In vivo, 56 patients with both type 2 diabetes and hypertension were enrolled and randomized to receive either telmisartan (40 mg) or candesartan (8 mg) for 3 months. Serum adiponectin, HbA1c levels, lipid profiles and blood pressure were recorded at the beginning and 3 months later. In vitro, differentiated 3T3-L1 adipocytes: were treated with telmisartan, candesartan, ploglitazone or vehicle for 24 h, and then adiponectin mRNA and protein levels were measured. The results showed that most of the metabolic parameters, including the lipid profiles, did not change significantly during the study in either group. However, the changes in serum adiponectin and plasma glucose over 3 months were significantly greater in the telmisartan group than in the candesartan group. In vitro, although the protein level of adiponectin was not significantly elevated, the mRNA expression of adiponectin was elevated 1.5-fold by telmisartan in 3T3-L1 adipocytes. Our findings suggest that telmisartan may have beneficial effects in type 2 diabetes beyond its antihypertensive effect.",
keywords = "Adiponectin, Candesartan, Peroxisome proliferator-activated receptor γ, Telmisartan",
author = "Satoru Yamada and Natsuko Ano and Kyoko Toda and Akira Kitaoka and Kaoru Shiono and Gaku Inoue and Koichiro Atsuda and Junichiro Irie",
year = "2008",
month = "4",
doi = "10.1291/hypres.31.601",
language = "English",
volume = "31",
pages = "601--606",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro

AU - Yamada, Satoru

AU - Ano, Natsuko

AU - Toda, Kyoko

AU - Kitaoka, Akira

AU - Shiono, Kaoru

AU - Inoue, Gaku

AU - Atsuda, Koichiro

AU - Irie, Junichiro

PY - 2008/4

Y1 - 2008/4

N2 - To examine the effects of telmisartan on peroxisome proliferator-activated receptor γ activation, we compared the effects of telmisartan with those of candesertan on adipocytokines and glucose and lipid metabolism in vivo and in vitro. In vivo, 56 patients with both type 2 diabetes and hypertension were enrolled and randomized to receive either telmisartan (40 mg) or candesartan (8 mg) for 3 months. Serum adiponectin, HbA1c levels, lipid profiles and blood pressure were recorded at the beginning and 3 months later. In vitro, differentiated 3T3-L1 adipocytes: were treated with telmisartan, candesartan, ploglitazone or vehicle for 24 h, and then adiponectin mRNA and protein levels were measured. The results showed that most of the metabolic parameters, including the lipid profiles, did not change significantly during the study in either group. However, the changes in serum adiponectin and plasma glucose over 3 months were significantly greater in the telmisartan group than in the candesartan group. In vitro, although the protein level of adiponectin was not significantly elevated, the mRNA expression of adiponectin was elevated 1.5-fold by telmisartan in 3T3-L1 adipocytes. Our findings suggest that telmisartan may have beneficial effects in type 2 diabetes beyond its antihypertensive effect.

AB - To examine the effects of telmisartan on peroxisome proliferator-activated receptor γ activation, we compared the effects of telmisartan with those of candesertan on adipocytokines and glucose and lipid metabolism in vivo and in vitro. In vivo, 56 patients with both type 2 diabetes and hypertension were enrolled and randomized to receive either telmisartan (40 mg) or candesartan (8 mg) for 3 months. Serum adiponectin, HbA1c levels, lipid profiles and blood pressure were recorded at the beginning and 3 months later. In vitro, differentiated 3T3-L1 adipocytes: were treated with telmisartan, candesartan, ploglitazone or vehicle for 24 h, and then adiponectin mRNA and protein levels were measured. The results showed that most of the metabolic parameters, including the lipid profiles, did not change significantly during the study in either group. However, the changes in serum adiponectin and plasma glucose over 3 months were significantly greater in the telmisartan group than in the candesartan group. In vitro, although the protein level of adiponectin was not significantly elevated, the mRNA expression of adiponectin was elevated 1.5-fold by telmisartan in 3T3-L1 adipocytes. Our findings suggest that telmisartan may have beneficial effects in type 2 diabetes beyond its antihypertensive effect.

KW - Adiponectin

KW - Candesartan

KW - Peroxisome proliferator-activated receptor γ

KW - Telmisartan

UR - http://www.scopus.com/inward/record.url?scp=44649097498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649097498&partnerID=8YFLogxK

U2 - 10.1291/hypres.31.601

DO - 10.1291/hypres.31.601

M3 - Article

C2 - 18633170

AN - SCOPUS:44649097498

VL - 31

SP - 601

EP - 606

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 4

ER -